We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First-Of-Its-Kind Online Tool to Revolutionize Treatment of High Blood Pressure

By HospiMedica International staff writers
Posted on 08 Sep 2025

High blood pressure affects as many as 1. More...

3 billion people and leads to around ten million deaths each year. Often called a silent killer, it can remain hidden until it causes heart attack, stroke, or kidney disease, with fewer than one in five patients keeping it under control. Traditional treatment decisions rely on noisy blood pressure readings that fluctuate greatly, making it hard to judge how well drugs work. Now, a first-of-its-kind online tool can predict how much different medications can lower blood pressure.

Researchers at the George Institute for Global Health (Sydney, Australia) have developed the Blood Pressure Treatment Efficacy Calculator, an online tool built from nearly 500 randomized clinical trials involving over 100,000 people. The calculator overcomes the challenge of selecting from dozens of drugs and doses by showing the average treatment effects observed across hundreds of trials. It groups therapies into low, moderate, and high intensity, similar to cholesterol management strategies.

The tool is based on a systematic review and meta-analysis published in The Lancet. A single antihypertensive drug typically lowers systolic pressure by just 8–9 mmHg, while most patients require reductions of 15–30 mmHg. By pooling evidence, the calculator allows doctors to match treatment to the degree of reduction needed, avoiding delays caused by adjusting therapy step by step and reducing the risk of misinterpretation from variable blood pressure readings.

The approach challenges the conventional “start low, go slow, measure and judge” method, which risks inertia and burdens patients with repeated visits. Instead, clinicians can target reductions upfront, prescribing optimal combinations earlier. The next step is a clinical trial where patients will be treated using the calculator’s guidance. Even modest improvements in global hypertension control could save millions of lives, highlighting its potential public health impact.

“Using the calculator challenges the traditional ‘start low, go slow, measure and judge’ approach to treatment, which comes with the high probability of being misled by BP readings, inertia setting in, or the burden on patients being too much,” said Anthony Rodgers, Senior Professorial Fellow at The George Institute for Global Health. “With this new method, you specify how much you need to lower blood pressure, choose an ideal treatment plan to achieve that based on the evidence, and get the patient started on that ideally sooner rather than later.”


Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Gold Member
Blood Gas Analyzer
i-Check200
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Surgical Techniques

view channel
Image: Researchers developed a handheld photothermal mid-infrared spectroscopic imaging (MIRSI) system that measures just 8 square inches. Probe light from a visible (red) diode laser and pump light from a modulated quantum cascade laser (QCL) are coupled into optical fibers and delivered to a flexible, handheld imager (blue dashed box). The beams are combined at a short-pass dichroic mirror and focused onto the sample using an off-axis parabolic mirror (OAP). (Image Credit:Rohith Reddy, University of Houston)

Handheld Infrared Imaging Device Supports Tumor Margin Assessment During Surgery

Accurately determining tumor margins during surgery remains challenging. Frozen-section pathology takes time and can miss residual disease, potentially leading to repeat surgery and delayed therapy.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.